A multicentre, randomised, double-blind, placebo-controlled dose finding phase 2 study of subcutaneously administered onercept in the treatment of patients with active Crohn's disease

(Various Trials for Title)
1 -(Serono)"A multicentre, randomised, double-blind, placebo-controlled dose finding phase 2 study of subcutaneously administered onercept in the treatment of patients with active crohn's disease"
(Protocol 22523) &
2 -(Serono)"Long term follow-up of crohn's disease patients having completed Serono protocol 22523, allowing for re-treatment with open-label onercept"
(Protocol 23054)
3 -(Elan)"A phase 3, multicentre, double-blind, placebo-controlled study of the safety, efficacy & tolerability of intravenous antegren (natilizumab) in subjects with moderately to severely active crohn's disease"
(Protocol AN100226-CD301)
4 -(Elan)"A phase 3, International, multicentre, double-blind, placebo-controlled study of the safety, efficacy & tolerability of intravenous antegren (natilizumab) (300mg monthly) in maintaining clinical response & remission in subjects with crohn's disease"
(Protocol AN100226-CD303)
5 -(Solvay)"A double-blind, placebo-controlled, randomised, multinational study to investigate the safety & efficacy of 2mg TID of cilansetron over 26 weeks in diarrhea-predominant irritable bowel syndrome subjects"
(Protocol S2413009)